Bausch + Lomb (BLCO) announced CE Mark approval for the LuxLife full range of vision intraocular lens. The preloaded IOL provides patients with natural, continuous vision, from distance to near.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch Health price target lowered to $8 from $9 at Raymond James
- Bausch + Lomb price target lowered to $15 from $20 at H.C. Wainwright
- Bausch + Lomb price target lowered to $12 from $15 at Wells Fargo
- Bausch + Lomb price target lowered to $11 from $17 at BofA
- Bausch + Lomb price target lowered to $13 from $14 at Citi